These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 38742463)

  • 1. Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases.
    Shumnalieva R; Velikova T; Monov S
    Int J Rheum Dis; 2024 May; 27(5):e15182. PubMed ID: 38742463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is There a Place for Chimeric Antigen Receptor-T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?
    Orvain C; Boulch M; Bousso P; Allanore Y; Avouac J
    Arthritis Rheumatol; 2021 Nov; 73(11):1954-1965. PubMed ID: 34042325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.
    Lyu X; Gupta L; Tholouli E; Chinoy H
    Rheumatology (Oxford); 2024 May; 63(5):1206-1216. PubMed ID: 37982747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions.
    Ohno R; Nakamura A
    Semin Arthritis Rheum; 2024 Aug; 67():152479. PubMed ID: 38810569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CAR T-cell therapy in rheumatology-What we know so far?].
    Hagen M; Wirsching A; Bohr D; Taubmann J; Müller F; Mackensen A; Grieshaber-Bouyer R; Schett G
    Z Rheumatol; 2024 Aug; 83(6):485-491. PubMed ID: 38780637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in CAR-T Therapy.
    Ali MB
    Cancer Control; 2024; 31():10732748241263713. PubMed ID: 38910268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in CAR-NK cell therapy for hematological malignancies.
    Yang R; Yang Y; Liu R; Wang Y; Yang R; He A
    Front Immunol; 2024; 15():1414264. PubMed ID: 39007146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approved CAR-T therapies have reproducible efficacy and safety in clinical practice.
    Goyco Vera D; Waghela H; Nuh M; Pan J; Lulla P
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378543. PubMed ID: 39104200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
    Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
    Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T Cell Therapy for Hematological Malignancies.
    Yang X; Wang GX; Zhou JF
    Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in CAR-T-cell therapy in T-cell malignancies.
    Zheng R; Zhu X; Xiao Y
    J Hematol Oncol; 2024 Jun; 17(1):49. PubMed ID: 38915099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.
    Li Y; Hu Z; Li Y; Wu X
    Front Immunol; 2024; 15():1409021. PubMed ID: 38751430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontiers in CAR-T cell therapy for autoimmune diseases.
    Li YR; Lyu Z; Chen Y; Fang Y; Yang L
    Trends Pharmacol Sci; 2024 Sep; 45(9):839-857. PubMed ID: 39147651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
    Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
    J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
    Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.